KDR and colorectal neoplasm: In this study, we demonstrated for the first time that the combination of anti-VEGFR-2 mAb with FTD/TPI resulted in increased overall antitumor efficacy with tolerability, and therefore, with no changes in the treatment safety profile compared to each respective monotherapy in a mouse colorectal tumor syngeneic model.